Technical Analysis for PLRX - Pliant Therapeutics, Inc.

Grade Last Price % Change Price Change
F 14.92 2.54% 0.37
PLRX closed up 2.9 percent on Wednesday, March 27, 2024, on 63 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
4 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Up

Date Alert Name Type % Chg
Oversold Stochastic Weakness 2.54%
Down 3 Days in a Row Weakness 5.52%
Oversold Stochastic Weakness 5.52%
Stochastic Reached Oversold Weakness 3.90%
Oversold Stochastic Weakness 3.90%
Oversold Stochastic Weakness 1.84%
Stochastic Buy Signal Bullish -1.58%
Doji - Bearish? Reversal -1.58%
Gapped Up Strength -1.58%
Up 3 Days in a Row Strength -1.58%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 3 hours ago
Rose Above 10 DMA about 6 hours ago
Down 1% about 7 hours ago
Rose Above Previous Day's High about 8 hours ago
10 DMA Resistance about 8 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Pliant Therapeutics, Inc. Description

Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant's lead product candidate, PLN-74809, is an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins that it is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting two Phase 2a trials of PLN-74809 for the treatment of IPF and plans to initiate a Phase 2a trial in PSC in the second half of 2020. Pliant's second product candidate, PLN-1474, is a small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis, or NASH, which Pliant has partnered with Novartis. PLN-1474 is currently undergoing a Phase 1 trial. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Alcohol Hepatitis Steatohepatitis Orphan Drug Non Alcoholic Fatty Liver Disease Hepatology Idiopathic Pulmonary Fibrosis Pulmonary Fibrosis Fibrosis Drug Design Liver Fibrosis Treatment Of Fibrosis Treatment Of Idiopathic Pulmonary Fibrosis Muscular Dystrophies Primary Sclerosing Cholangitis Integrin

Is PLRX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 30.85
52 Week Low 12.605
Average Volume 403,690
200-Day Moving Average 16.69
50-Day Moving Average 16.22
20-Day Moving Average 15.20
10-Day Moving Average 14.72
Average True Range 0.86
RSI (14) 42.20
ADX 24.72
+DI 12.44
-DI 22.01
Chandelier Exit (Long, 3 ATRs) 15.42
Chandelier Exit (Short, 3 ATRs) 16.65
Upper Bollinger Bands 16.55
Lower Bollinger Band 13.86
Percent B (%b) 0.26
BandWidth 17.72
MACD Line -0.52
MACD Signal Line -0.48
MACD Histogram -0.0375
Fundamentals Value
Market Cap 871.49 Million
Num Shares 59.9 Million
EPS -2.78
Price-to-Earnings (P/E) Ratio -5.23
Price-to-Sales 286.05
Price-to-Book 2.02
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 15.74
Resistance 3 (R3) 15.72 15.30 15.54
Resistance 2 (R2) 15.30 15.00 15.31 15.47
Resistance 1 (R1) 14.93 14.82 15.12 14.95 15.41
Pivot Point 14.51 14.51 14.61 14.52 14.51
Support 1 (S1) 14.14 14.21 14.33 14.16 13.69
Support 2 (S2) 13.72 14.03 13.73 13.63
Support 3 (S3) 13.35 13.72 13.56
Support 4 (S4) 13.37